In this systematic review of patients post-ACS on anti platelet therapy, the use of newer oral anticoagulants (rivaroxaban, apixaban, dabigatran) was associated with much higher risk of bleeding (odd ratio 3, CI 2.2 to 4.2), a moderate reduction in stent thrombosis/ischemia, and no overall change in mortality, compared to placebo. The overall net benefit of these agents was no different than placebo. The new oral anticoagulants do not appear to benefit patients post-ACS (abstract).
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc. Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them. If I am […]